Anticancer Platinum Compounds


Platinum(II) complexes (Pt1) are new chemical entities of potential targeted chemotherapeutics for combating advanced stage

  • Anticancer Platinum Compounds 0
Commercialisation opportunities
LSCCB, HKU and start-up company GoldPorp Pharma Ltd are developing the proprietary anticancer metal compounds with possibility of collaborative research projects and licensing.
Problem addressed

Despite advances in new modalities of cancer therapy, chemotherapy may be still needed for treatment of some advanced-stage cancers. Pt1 demonstrate superior antitumour activities and better tolerance compared to standard platinum based chemotherapy in in vitro and in vivo cancer models.

  • Pt1 suppress tumour growth in breast, nasopharyngeal and lung cancer in mice and also patient-derived organoid samples.
  • Pt1 target cancer cell invasion proteins and arrest metastatic tumour growth in triple negative breast cancer model.
  • Pt1 demonstrate desirable drug disposition and metabolism profile and are well tolerated in mice compared to cisplatin.
Key impact
  • Pt1 and derivatives are new chemical entities that have been shown to target a number of yet-to-drugged anticancer molecular targets (e.g. HSP60, VIM, NDKA, NPM, YB1, PDRX1).
  • Pt1 exhibit effective anti-tumour activities and impede metastasis in advanced-stage cancer models.
  • Investigational New Drug application in preparation


  • US8,530,659
  • ZL201080049820
  • EP2493896

Laboratory for Synthetic Chemistry and Chemical Biology (LSCCB) is an R&D centre funded by Health@InnoHK progamme of Innovation and Technology Commission of  HKSAR. Established in 2020, LSCCB is operated with tripartite joint collaboration of The University of Hong Kong, Imperial College London and Peking University. LSCCB aims at integrating chemical and biomedical sciences to develop new molecular medicines and diagnostic tools for the treatment and analysis of human diseases, in particular, cancer. LSCCB currently assembles more than 20 principal investigators for 4 major research programmes including (a) Synthetic Chemistry; (b) Chemical Biology of Natural Products and Chinese Medicine; (c) Metal Anticancer Medicine, Diagnostics and Theranostics; and (d) Multi-Omics and Innovative Analytical Technologies for InnoHealth.